Mark Scholz, M.D.
As a double board-certified medical specialist, Dr. Mark Scholz is the Executive Director of the Prostate Cancer Research Institute, a non-profit organization dedicated to patient education and research. He received his medical degree from Creighton University in Omaha, completed his internship and residency in Internal Medicine, and subsequently his Medical Oncology fellowship at the University of Southern California Medical Center. The physician's society memberships include the American Society of Clinical Oncology, the American Society of Therapeutic Radiology, the American Urologic Associate, and the European Associate of Urology.
Dr. Mark Scholz works as a primary investigator, actively supervising a number of ongoing prostate cancer clinical trials, and has authored and co-authored over 90 scholarly articles and abstracts in his area of expertise. He is a strong advocate for patient empowerment, being the co-author of the books "Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment or Loss of Potency" and "The Key to Prostate Cancer: 30 Experts Explain 15 Stages of Prostate Cancer". Dr. Mark Scholz served as Oncology Director at the Memorial Campus of the Centinela Freeman Regional Medical Center from 1996 to 2001. He also has a Bachelor of Arts in Biochemistry, which he earned from Occidental College. The physician has approximately 40 years of professional experience and is the recipient of the Most Compassionate Doctor award.
Conditions Dr. Mark Scholz Treats at Cedars-Sinai Marina del Rey Hospital
Insurance Accepted
- Assurant Health
- Aetna
- Cigna
- Coventry Health Care
- HealthNet
- Humana
- Medicare
- Tricare
- United Healthcare
Languages Spoken
- Chinese
- English
- Spanish
Education & Training
Medical Degree
Creighton University
Internship(s)
LAC+USC Medical Center, Internal Medicine
Residency(ies)
LAC+USC Medical Center, Internal Medicine
Fellowship(s)
LAC+USC Medical Center, Medical Oncology, Chief Fellow
Memberships & Affiliations
Fellow of the American College of Physicians
American Medical Association
American Society of Clinical Oncology
American Society for Therapeutic Radiology & Oncology
American Urological Association
California Medical Association
Los Angeles County Medical Association
Publications & Media
-
Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America.
Anthony M. Joshua, Neal D. Shore, Fred Saad, Kim N. Chi, Carl A. Olsson, Urban Emmenegger, Mark C. Scholz, William R. Berry, Som D. Mukherjee, Eric Winquist, Naomi B. Haas, Margaret A. Foley, Carl Dmuchowski, Frank Perabo, Mohammad Hirmand, Nahla Hasabou, Dana E. Rathkopf
-
Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer.
Julianna Higa, Kirk Wilenius, Shannon Savino, Claire Larsen, Mark C. Scholz, Nicholas J. Vogelzang
-
Outcomes of Treatment vs. Observation of Localized Prostate Cancer in Elderly Men.
Mark C. Scholz, MD, Richard Y. Lam, MD, Laurence Klotz, MD, FRCSC
-
Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time off Period.
Mark C. Scholz, Robert I. Jennrich, Stephen B. Strum, Henry Johnson, Brad W. Guess, Richard Y. Lam
-
Modified Citrus Pectin (MCP) Increases the Prostate-specific Antigen Doubling Time in Men with Prostate Cancer: a Phase II Pilot Study.
Guess, B. W., Scholz, M. C., Strum, S. B., Lam, R. Y., Johnson, H. J., Jennrich, R. I.
-
Anaemia Associated with Androgen Deprivation in Patients with Prostate Cancer Receiving Combined Hormone Blockade.
Strum, S. B., McDermed, J. E., Scholz, M. C., Johnson, H., Tisman, G.